

MAINE STATE LEGISLATURE

The following document is provided by the
LAW AND LEGISLATIVE DIGITAL LIBRARY
at the Maine State Law and Legislative Reference Library
<http://legislature.maine.gov/lawlib>



Reproduced from electronic originals
(may include minor formatting differences from printed original)



126th MAINE LEGISLATURE

FIRST REGULAR SESSION-2013

Legislative Document

No. 627

S.P. 217

In Senate, February 21, 2013

An Act Relating to Orally Administered Cancer Therapy

Reference to the Committee on Insurance and Financial Services suggested and ordered printed.

A handwritten signature in black ink, appearing to read 'D M Grant'.

DAREK M. GRANT
Secretary of the Senate

Presented by Senator CAIN of Penobscot.
Cosponsored by Representative HOBBS of Saco and
Senators: President ALFOND of Cumberland, CRAVEN of Androscoggin, CUSHING of
Penobscot, GRATWICK of Penobscot, Representatives: McCABE of Skowhegan, POULIOT
of Augusta.

1 **Be it enacted by the People of the State of Maine as follows:**

2 **Sec. 1. 24 MRSA §2320-H** is enacted to read:

3 **§2320-H. Orally administered cancer therapy**

4 All individual and group nonprofit hospital and medical services plan policies,
5 contracts and certificates and all nonprofit health care plan policies, contracts and
6 certificates that provide coverage for cancer chemotherapy treatment must provide
7 coverage for prescribed, orally administered anticancer medications used to kill or slow
8 the growth of cancerous cells that is equivalent to the coverage provided for
9 intravenously administered or injected anticancer medications. An increase in patient
10 cost sharing for anticancer medications may not be used to achieve compliance with this
11 section.

12 **Sec. 2. 24-A MRSA §2745-H** is enacted to read:

13 **§2745-H. Orally administered cancer therapy**

14 All individual insurance policies, contracts and certificates that provide coverage for
15 cancer chemotherapy treatment must provide coverage for prescribed, orally administered
16 anticancer medications used to kill or slow the growth of cancerous cells that is
17 equivalent to the coverage provided for intravenously administered or injected anticancer
18 medications. An increase in patient cost sharing for anticancer medications may not be
19 used to achieve compliance with this section.

20 **Sec. 3. 24-A MRSA §2837-I** is enacted to read:

21 **§2837-I. Orally administered cancer therapy**

22 All group insurance policies, contracts and certificates that provide coverage for
23 cancer chemotherapy treatment must provide coverage for prescribed, orally administered
24 anticancer medications used to kill or slow the growth of cancerous cells that is
25 equivalent to the coverage provided for intravenously administered or injected anticancer
26 medications. An increase in patient cost sharing for anticancer medications may not be
27 used to achieve compliance with this section.

28 **Sec. 4. 24-A MRSA §4234-F** is enacted to read:

29 **§4234-F. Orally administered cancer therapy**

30 All individual and group health maintenance organization policies, contracts and
31 certificates that provide coverage for cancer chemotherapy treatment must provide
32 coverage for prescribed, orally administered anticancer medications used to kill or slow
33 the growth of cancerous cells that is equivalent to the coverage provided for
34 intravenously administered or injected anticancer medications. An increase in patient
35 cost sharing for anticancer medications may not be used to achieve compliance with this
36 section.

